Navigation Links
BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100)
Date:7/28/2011

rious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, amifampridine phosphate (3,4-diaminopyridine phosphate), which is currently in Phase III clinical development for the treatment of LEMS in the U.S., PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.Forward-Looking StatementThis press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, including, without li
'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies
2. BioMarin to Present at the UBS Global Specialty Pharmaceuticals Conference
3. BioMarin to Host First Quarter 2011 Financial Results Conference Call and Webcast on Thursday, April 28 at 5:00 p.m. ET
4. BioMarin to Host Third Quarter 2010 Financial Results Conference Call and Webcast on Thursday, October 28 at 5:00 p.m. ET
5. BioMarin to Present at the Barclays Capital Global Healthcare Conference
6. BioMarins Chief Executive Jean-Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times
7. BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
8. BioMarin to Present at the Morgan Stanley Healthcare Conference
9. BioMarin to Present at the Baird Healthcare Conference
10. BioMarin to Present at the Jefferies Healthcare Conference
11. BioMarin to Present at the Goldman Sachs Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... D.C., September 30, 2014 Applying a well-known ... researchers at Harvard University has demonstrated the ability ... -- work that holds promise for making future, ... detailing the sides of next-gen rocket ships and ... light passes through oil in water, it becomes ...
(Date:9/30/2014)... Shimadzu Scientific Instruments has released the DSES-1000 long-travel ... for measuring displacement in rubber and other soft ... distance, the DSES-1000 can measure elongations up to ... mm. In addition, it achieves +/- 0.2 percent ... +/- 100 µm below 50-mm stroke. , The ...
(Date:9/30/2014)... , Sept. 30, 2014  RegeneRx Biopharmaceuticals, Inc. ... that it has received a Canadian Patent for ... Peptides.  This patent includes claims using thymosin beta ... actin-sequestering peptides for these purposes.  The patent will ... Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
(Date:9/30/2014)... 2014  KemPharm, Inc., a clinical-stage specialty pharmaceutical ... proprietary new molecular entity (NME) prodrugs, announced today ... (USPTO) issued U.S. Patent No. 8,816,083 to KemPharm ... Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates of ... The patent, which extends through 2032, ...
Breaking Biology Technology:Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... ARBOR, Mich., July 13 Accuri Cytometers, Inc. today ... financing. The financing included current investors Fidelity Biosciences, ... well as the InvestMichigan! Program co-managed by Credit Suisse. ... D financing to provide additional working and growth capital ...
... ... Pharmaceutical Production Executive to Head its Two U.S. Contract Manufacturing Facilities , ... Hackensack, NJ (Vocus) July 13, ... Daryl LeSueur as Vice President of Manufacturing Operations. As head of Manufacturing ...
... advantage in the media. A new study by Dr. ... the journal of Israel,s National Security College, describes how ... too. "Information warfare" plays a crucial ... so than conventional weapons. Therefore, the information warfare against ...
Cached Biology Technology:Accuri Cytometers Completes $4 Million Series D Financing 2Accuri Cytometers Completes $4 Million Series D Financing 3Accuri Cytometers Completes $4 Million Series D Financing 4Accuri Cytometers Completes $4 Million Series D Financing 5Progenitor Cell Therapy Appoints VP of Manufacturing Operations 2Progenitor Cell Therapy Appoints VP of Manufacturing Operations 3Information warfare in the 21st century: Ideas are sometimes stronger than bombs 2
(Date:9/30/2014)... . , Animals ... such as exposure to predators. Researchers from the Max ... study on different populations of great tits that risk-taking ... High metabolic rates and low temperatures were associated with ... more likely to approach potential predators. , The readiness ...
(Date:9/29/2014)... , coupled with a high-fat diet, may cause animals to ... mBio , the online open-access journal of the American Society ... Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal observed that mice ... weight when fed a high-fat diet. Mice that did not ... consuming a high-fat diet, and mice that had C. ...
(Date:9/29/2014)... pizza in school? According to a new Food and ... chef-made meals can increase participation in the National School ... consumption of vegetables by 16%! , Chefs Move to ... campaign, pairs chefs with schools in order to provide ... school food service workers. , A CMTS event was ...
Breaking Biology News(10 mins):Risky metabolism 2Gut bacteria promote obesity in mice 2Chefs move to schools can increase school meal participation and vegetable intake among students 2
... Scientists have found that a large proportion of infants ... disease. The disease is the most prevalent acute wheezing ... admission to hospital in the first year of life in ... admitted to hospital for bronchiolitis - needing oxygen and help ...
... from small rings of naturally occurring plant DNA can ... embryonic plants where they are expressed, duplicated as plant ... -- a long-term goal for those interested in improving ... issue of PLoS-Genetics, a team of academic and commercial ...
... Research Hospital have identified the cell that gives rise to ... growth and development. The finding suggests for the first time ... induce fully developed neurons to multiply and coax the injured ... work appears in the Oct. 19 issue of the journal ...
Cached Biology News:Scientists find predisposition to bronchiolitis in some babies 2Transgenics transformed 2Transgenics transformed 3St. Jude identifies the specific cell that causes eye cancer, disproving long-held theory 2St. Jude identifies the specific cell that causes eye cancer, disproving long-held theory 3
... Deletion Machine is based on the simple, ... by Goryshin and Reznikoff, and by York ... of deletions and inversions by intramolecular transposition ... plasmid vector. Although most researchers will be ...
... I provides reagents and a protein standard for ... agents and detergents. The RC DC protein assay ... and standards sufficient for 500 standard assays: 250 ... II, 250 ml alkaline copper tartrate solution, 2 ...
... crystalline solid. PROTECT FROM LIGHT. Useful in cell activation ... Purity: ≥98% by TLC. Soluble in DMSO or ... a 10 mM stock in DMSO is recommended. Microliter ... 2 O with rapid mixing (e.g. 10 μl into ...
... Both compact and lightweight, the Moticam ... microscope through the eyepiece, eyetube, or trinocular ... easy to use Plug-and-Play Images 2.0ML software ... Image manipulation tools to maximize resolution for ...
Biology Products: